Dr Matthew Williams
Dr Matt Williams specialises in the treatment of brain tumours, including benign and malignant tumours and brain metastases. He has expanded the use of a second course of radiotherapy (re-irradiation), particularly in combination with chemotherapy. He is one of the few clinicians in the UK to have experience across the range of all three stereotactic platforms (LINAC, CyberKnife and GammaKnife) for delivering highly focused radiotherapy. At AOA体育平台 he chairs the brain tumour (neuro-oncology) MDT.
Bio
Dr Matthew Williams trained in Birmingham, before moving to London where he trained at the Hammersmith Hospital.
He completed his clinical oncology training in London, followed by a PhD with the Advanced Computation Lab at CRUK/UCL. He was appointed as a consultant at Imperial College Healthcare NHS Trust in February 2012, where he specialises in neuro-oncology and is joint MDT lead for neuro-oncology.
He is an Honorary Senior Fellow at Imperial College, where he leads the Computational Oncology Group. He sits on the NCRI Brain Tumour clinical trials group, and has a particular interest in studies looking at novel approaches to improving current treatments in neuro-oncology.
He chairs the neuro-oncology MDT at AOA体育平台, and has worked to make AOA体育平台 the only site in the UK that offers the INTRAGO-II trial of intra-operative radiotherapy in newly diagnosed patients with GBM.
More information
- Neuro-oncology
- Brain tumour chemotherapy
- Brain tumour radiotherapy
- Brain metastases
- Recurrent Glioma
- Stereotactic radiotherapy
- SRS
- Radiotherapy-chemotherapy combinations for glioma
- Metabolic approaches to modulating radiotherapy response in glioma
- Computational Oncology
- Consultant Clinical Oncologist
Imperial College Healthcare NHS Trust - Honorary Senior Fellow
Imperial College
- Honorary Senior Research Fellow
Imperial College London
Year qualified 1999
Birmingham 1999